Literature DB >> 18838708

Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.

Sarah A McLaughlin1, Mary J Wright, Katherine T Morris, Michelle R Sampson, Julia P Brockway, Karen E Hurley, Elyn R Riedel, Kimberly J Van Zee.   

Abstract

PURPOSE: Sentinel lymph node (SLN) biopsy was adopted for the staging of the axilla with the assumption that it would reduce the risk of lymphedema in women with breast cancer. This study was undertaken to examine patient perceptions of lymphedema and use of precautionary behaviors several years after axillary surgery. PATIENTS AND METHODS: Nine hundred thirty-six women who underwent SLN biopsy (SLNB) alone or SLNB followed by axillary lymph node dissection (SLNB/ALND) between June 1, 1999, and May 30, 2003, were evaluated at a median of 5 years after surgery. Patient-perceived lymphedema and avoidant behaviors were assessed through interview and administered a validated instrument, and compared with arm measurements.
RESULTS: Current arm swelling was reported in 3% of patients who received SLNB alone versus 27% of patients who received SLNB/ALND (P < .0001), as compared with 5% and 16%, respectively, with measured lymphedema. Only 41% of patients reporting arm swelling had measured lymphedema, and 5% of patients reporting no arm swelling had measured lymphedema. Risk factors associated with reported arm swelling were greater body weight (P < .0001), higher body mass index (P < .0001), infection (P < .0001), and injury (P = .007) in the ipsilateral arm since surgery. Patients followed more precautions if they had measured or perceived lymphedema.
CONCLUSION: Body weight, infection, and injury are significant risk factors for perceiving lymphedema. There is significant discordance between the presence of measured and patient-perceived lymphedema. When compared to SLNB/ALND, SLNB-alone results in a significantly lower rate of patient-perceived arm swelling 5 years postoperatively, and is perceived by fewer women than are measured to have it.

Entities:  

Mesh:

Year:  2008        PMID: 18838708      PMCID: PMC2652092          DOI: 10.1200/JCO.2008.16.3766

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

1.  Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer.

Authors:  Emmanuel Barranger; Gil Dubernard; José Fleurence; Martine Antoine; Emile Darai; Serge Uzan
Journal:  J Surg Oncol       Date:  2005-10-01       Impact factor: 3.454

2.  Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients.

Authors:  Igor Langer; Ulrich Guller; Gilles Berclaz; Ossi R Koechli; Gabriel Schaer; Mathias K Fehr; Thomas Hess; Daniel Oertli; Lucio Bronz; Beate Schnarwyler; Edward Wight; Urs Uehlinger; Eduard Infanger; Daniel Burger; Markus Zuber
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

3.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

4.  Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer.

Authors:  J S Rietman; J H B Geertzen; H J Hoekstra; P Baas; W V Dolsma; J de Vries; J W Groothoff; W H Eisma; P U Dijkstra
Journal:  Eur J Surg Oncol       Date:  2006-01-04       Impact factor: 4.424

5.  Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women.

Authors:  Larissa K F Temple; Roberta Baron; Hiram S Cody; Jane V Fey; Howard T Thaler; Patrick I Borgen; Alexander S Heerdt; Leslie L Montgomery; Jeanne A Petrek; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

6.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Authors:  Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

7.  Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer.

Authors:  D Kay Blanchard; John H Donohue; Carol Reynolds; Clive S Grant
Journal:  Arch Surg       Date:  2003-05

8.  Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.

Authors:  Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2006-03-02       Impact factor: 5.344

9.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

10.  Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients.

Authors:  F Peintinger; R Reitsamer; H Stranzl; G Ralph
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

View more
  44 in total

Review 1.  Lymphaticovenular anastomosis for breast cancer-related upper extremity lymphedema: a literature review.

Authors:  Antonio J Forte; Andrea Sisti; Maria T Huayllani; Daniel Boczar; Gabriela Cinotto; Pedro Ciudad; Oscar J Manrique; Xiaona Lu; Sarah McLaughlin
Journal:  Gland Surg       Date:  2020-04

2.  Lymphoedema and health-related quality of life by early treatment in long-term survivors of breast cancer. A comparative retrospective study up to 15 years after diagnosis.

Authors:  Katarina Y Karlsson; Imke Wallenius; Lena B Nilsson-Wikmar; Henrik Lindman; Birgitta B K Johansson
Journal:  Support Care Cancer       Date:  2015-03-06       Impact factor: 3.603

3.  Lymphedema in Canada: a qualitative study to help develop a clinical, research, and education strategy.

Authors:  P Hodgson; A Towers; D H Keast; A Kennedy; R Pritzker; J Allen
Journal:  Curr Oncol       Date:  2011-12       Impact factor: 3.677

4.  Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer.

Authors:  Ann Marie Flores; Jason Nelson; Lee Sowles; Rebecca G Stephenson; Kathryn Robinson; Andrea Cheville; Antoinette P Sander; William J Blot
Journal:  Phys Ther       Date:  2020-03-10

5.  Frequency of Early-Stage Lymphedema and Risk Factors in Postoperative Patients with Breast Cancer.

Authors:  Aykut Soyder; Engin Taştaban; Serdar Özbaş; Şükrü Boylu; Hedef Özgün
Journal:  J Breast Health       Date:  2014-04-01

6.  Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.

Authors:  Ting Bao; Wanqing Iris Zhi; Emily A Vertosick; Qing Susan Li; Janice DeRito; Andrew Vickers; Barrie R Cassileth; Jun J Mao; Kimberly J Van Zee
Journal:  Breast Cancer Res Treat       Date:  2018-03-08       Impact factor: 4.872

7.  Complication rates in patients with negative axillary nodes 10 years after local breast radiotherapy after either sentinel lymph node dissection or axillary clearance.

Authors:  A Gabriella Wernicke; Michael Shamis; Kulbir K Sidhu; Bruce C Turner; Yevgenyia Goltser; Imraan Khan; Paul J Christos; Lydia T Komarnicky-Kocher
Journal:  Am J Clin Oncol       Date:  2013-02       Impact factor: 2.339

8.  The role of occupational upper extremity use in breast cancer related upper extremity lymphedema.

Authors:  Gulgun Tahan; Ronald Johnson; Lisa Mager; Atilla Soran
Journal:  J Cancer Surviv       Date:  2009-12-06       Impact factor: 4.442

9.  Hypofractionated irradiation of infra-supraclavicular lymph nodes after axillary dissection in patients with breast cancer post-conservative surgery: impact on late toxicity.

Authors:  Marina Guenzi; Gladys Blandino; Maria Giuseppina Vidili; Deborah Aloi; Elena Configliacco; Elisa Verzanini; Elena Tornari; Francesca Cavagnetto; Renzo Corvò
Journal:  Radiat Oncol       Date:  2015-08-20       Impact factor: 3.481

10.  Risk factors associated with breast cancer-related lymphedema in the WHEL Study.

Authors:  Sally A Dominick; Lisa Madlensky; Loki Natarajan; John P Pierce
Journal:  J Cancer Surviv       Date:  2012-12-05       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.